Preclinical to Clinical Translational Pharmacology of ADCs and Combinations
Time: 11:00 am
day: Conference Day Two
Details:
- Preclinical models often overpredict ADC clearance and efficacy; clinical translation requires biomarkers and modelling
- Payload toxicities dominate; humans show lower tolerance than animals; combinations add overlapping risks
- Preclinical PDXs exaggerate responses; clinical outcomes are limited by heterogeneity and resistance
